YRC Worldwide to Present at Stephens Fall Investment Conference
Nov 07, 2016 21:05 pm UTC| Business
OVERLAND PARK, Kan., Nov. 07, 2016 -- YRC Worldwide Inc. (NASDAQ:YRCW) today announced that James Welch, Chief Executive Officer and Jamie Pierson, Chief Financial Officer will deliver a company presentation at 9:00...
Stereotaxis Reports 2016 Third Quarter Financial Results
Nov 07, 2016 21:05 pm UTC| Business
Completed $24 million private placement equity financingRetired all outstanding debt at significant discountAppointed three board members with extensive medical device experienceShipped fifth Niobe® ES system to JapanGrew...
Nivalis Therapeutics Reports Third Quarter 2016 Financial Results
Nov 07, 2016 21:05 pm UTC| Business
BOULDER, Colo., Nov. 07, 2016 -- Nivalis Therapeutics, Inc. (NASDAQ:NVLS),a clinical-stage pharmaceutical company focused on treating people with cystic fibrosis (CF), today reported financial results and recent...
Hallmark Financial Services, Inc. Announces Third Quarter 2016 Earnings Results
Nov 07, 2016 21:05 pm UTC| Business
FORT WORTH, Texas, Nov. 07, 2016 -- Hallmark Financial Services, Inc. (NASDAQ:HALL) today announced earnings for its third fiscal quarter ended September 30, 2016, including the following highlights: 3rd quarter...
Nov 07, 2016 21:05 pm UTC| Business
SEATTLE, Nov. 07, 2016 -- NanoString Technologies, Inc.(NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, has begun accepting applications to a Technology...
Karyopharm Reports Third Quarter 2016 Financial Results and Highlights Recent Progress
Nov 07, 2016 21:05 pm UTC| Business
− Recent Utilization of ATM Financing Facility Nets Proceeds of $47 million; Extends Cash Runway to end of 2018, Beyond STORM Expansion Data Readout – − Updated Clinical Data from STORM and STOMP Studies to be Reported...
TRACON Pharmaceuticals to Present at Upcoming Investment Conferences
Nov 07, 2016 21:05 pm UTC| Business
SAN DIEGO, Nov. 07, 2016 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related...